Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
401 stopped studies mapped to Breast Carcinoma and descendants · 95% state a reason
Over the 401 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03674827 | Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC | Phase 1 | terminated | Sep 18, 2018 | Pfizer | The study was terminated due to the review of the asset (VBIR-2) within the Sponsor's oncology… | Safety / toxicity |
| NCT03498716 | A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant…(IMpassion030) | Phase 3 | terminated | Apr 17, 2018 | Hoffmann-La Roche | The study was terminated by the sponsor following interim analysis as the primary endpoint of iDFS… | Efficacy / futility |
| NCT04205786 | Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer | N/A | withdrawn | Dec 19, 2019 | Case Comprehensive Cancer Center | Logistics requirements, research cancelled | Other (stated, no rule matched) |
| NCT02037529 | Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients… | Phase 3 | suspended | Jan 16, 2014 | Academic and Community Cancer Research United | Total enrollment number is being lowered | Enrollment / accrual |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant… | Phase 1 / Phase 2 | terminated | Oct 3, 2023 | Tango Therapeutics, Inc. | Terminated due to safety | Safety / toxicity |
| NCT03387085 | QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed… | Phase 1 / Phase 2 | terminated | Dec 29, 2017 | ImmunityBio, Inc. | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT05156606 | Testosterone & Tamoxifen Trial(T&T) | N/A | terminated | Dec 14, 2021 | University Medical Center Groningen | Five patients were included; it did not succeed in recruiting the target number of 6 patients. This… | Enrollment / accrual |
| NCT05672342 | Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy… | Early Phase 1 | withdrawn | Jan 5, 2023 | City of Hope Medical Center | withdrawn | Other (stated, no rule matched) |
| NCT04120246 | Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer | Phase 1 | suspended | Oct 9, 2019 | Veana Therapeutics | Study placed on hold. | Other (stated, no rule matched) |
| NCT02876640 | Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer | Phase 1 | terminated | Aug 24, 2016 | National Cancer Institute (NCI) | Inadequate Accrual Rate | Enrollment / accrual |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2018 | ADC Therapeutics S.A. | Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity.… | Other (stated, no rule matched) |
| NCT04927884 | A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast… | Phase 1 / Phase 2 | terminated | Jun 16, 2021 | ImmunityBio, Inc. | low enrollment | Enrollment / accrual |
| NCT03199040 | Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple… | Phase 1 | terminated | Jun 26, 2017 | Washington University School of Medicine | Drugs/equipment unavailable and insufficient funding | Funding |
| NCT04726332 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors… | Phase 1 | terminated | Jan 27, 2021 | Exelixis | Business reasons | Sponsor / business decision |
| NCT06057636 | Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study | N/A | withdrawn | Sep 28, 2023 | The University of Tennessee, Knoxville | Unable to recruit participants | Enrollment / accrual |
| NCT05073172 | StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or… | N/A | withdrawn | Oct 11, 2021 | OHSU Knight Cancer Institute | study staff transition | Other (stated, no rule matched) |
| NCT05134194 | A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy… | Phase 3 | terminated | Nov 24, 2021 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Sponsor R \& D Strategy Adjustment\] | Sponsor / business decision |
| NCT02540330 | A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant(007) | Phase 2 | terminated | Sep 3, 2015 | Atossa Therapeutics, Inc. | Business decision (See Detailed Description) | Sponsor / business decision |
| NCT06137651 | Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of… | Phase 1 | withdrawn | Nov 18, 2023 | Northwestern University | Study terminated by the sponsor | Other (stated, no rule matched) |
| NCT03361800 | Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage… | Early Phase 1 | terminated | Dec 5, 2017 | UNC Lineberger Comprehensive Cancer Center | Funding withdrawn. | Funding |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | Phase 1 | terminated | Dec 31, 2020 | Ikena Oncology | Sponsor business decision. | Sponsor / business decision |
| NCT05967286 | Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment… | Phase 2 | withdrawn | Aug 1, 2023 | National Cancer Institute (NCI) | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT05689359 | Evaluation of Hydroxychloroquine to Prevent CIPN | Phase 2 | withdrawn | Jan 19, 2023 | University of Arizona | Per Principal Investigator, it is not feasible to move forward with this trial. | Investigator |
| NCT03709082 | Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2… | Phase 1 / Phase 2 | terminated | Oct 17, 2018 | University of Kansas Medical Center | Low accrual | Enrollment / accrual |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME… | Phase 1 | terminated | Mar 18, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT05474690 | A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of… | Phase 3 | withdrawn | Jul 26, 2022 | Henan Cancer Hospital | The new treatment plan for HER2 positive breast cancer has entered the diagnosis and treatment… | Other (stated, no rule matched) |
| NCT04461600 | A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast…(TENACITY) | Phase 2 | terminated | Jul 8, 2020 | Ayala Pharmaceuticals, Inc, | Sponsor's decision | Sponsor / business decision |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | Phase 1 | terminated | Jul 18, 2019 | Kite, A Gilead Company | The sponsor finds the risk/benefit analysis unfavorable and has terminated the study. | Other (stated, no rule matched) |
| NCT05238831 | SMMART Adaptive Clinical Treatment (ACT) Trial | Early Phase 1 | withdrawn | Feb 14, 2022 | OHSU Knight Cancer Institute | Withdrawn due to a change in therapeutic interventions. | Other (stated, no rule matched) |
| NCT05315687 | Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy | Phase 2 | withdrawn | Apr 7, 2022 | Emory University | Study is being closed because PI left Emory | Investigator |
| NCT03970967 | Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma… | N/A | terminated | Jun 3, 2019 | Alpha Tau Medical LTD. | Difficulty in recruiting patients | Enrollment / accrual |
| NCT03992131 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants… | Phase 1 / Phase 2 | terminated | Jun 20, 2019 | pharmaand GmbH | Due to a change in development priorities, no further clinical development of the lucitanib plus… | Other (stated, no rule matched) |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Phase 1 | terminated | Jan 28, 2020 | Atreca, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04756505 | Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of… | Phase 1 | withdrawn | Feb 16, 2021 | M.D. Anderson Cancer Center | Per Sponsor Request-no longer manufacturing the study drug | Drug supply |
| NCT04690855 | A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative…(TARA) | Phase 2 | terminated | Dec 31, 2020 | Mylin A. Torres, MD | This study has been terminated due to Lack of Accrual. | Enrollment / accrual |
| NCT03861403 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus… | Phase 1 | terminated | Mar 4, 2019 | Leap Therapeutics, Inc. | Product development discontinued unrelated to safety. | Safety / toxicity |
| NCT02963363 | Adapted Physical Activity for Breast Cancer HER2 Positive Patient(APACAN2) | N/A | terminated | Nov 15, 2016 | Centre Jean Perrin | Insufficient recruitment | Enrollment / accrual |
| NCT01931709 | FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer | N/A | terminated | Aug 29, 2013 | University of Washington | Terminated due to end of funding | Funding |
| NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine… | Phase 1 | withdrawn | Oct 26, 2020 | QuantumLeap Healthcare Collaborative | Study withdrawn as scientific interest in pursuing the SYD985+Paclitaxel combination has diminished. | Other (stated, no rule matched) |
| NCT02127073 | Pilot Study of Oxytocin and microRNA Identification in NAF, Serum, and Tissue in Women… | Phase 2 | terminated | Apr 30, 2014 | Montefiore Medical Center | Could not identify collaborator and secure additional funding after transferring the record to… | Funding |
| NCT04054752 | Vaccine Response With NT-I7 | Phase 1 | withdrawn | Aug 13, 2019 | National Cancer Institute (NCI) | No subjects enrolled. | Enrollment / accrual |
| NCT05436808 | Partial Chest Wall Radiation Therapy After Surgery for Lymph Node Negative Breast Cancer | Early Phase 1 | withdrawn | Jun 29, 2022 | Stony Brook University | No eligible participants identified | Other (stated, no rule matched) |
| NCT05032079 | Subzero and Scorpion Trial | N/A | withdrawn | Sep 2, 2021 | Larkin Community Hospital | Study Period Ended / Not Completed | Other (stated, no rule matched) |
| NCT01873833 | Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating… | Phase 2 | terminated | Jun 10, 2013 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT04139993 | RBX7455 Before Surgery for the Treatment of Operable Breast Cancer | Phase 1 | terminated | Oct 25, 2019 | Mayo Clinic | poor accrual | Enrollment / accrual |
| NCT03803761 | A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer | Phase 1 / Phase 2 | withdrawn | Jan 15, 2019 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT05371860 | Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete… | Phase 2 | withdrawn | May 12, 2022 | Armando Giuliano | PI voluntarily closed the study. Will be reopened as a national cooperative group trial. | Other (stated, no rule matched) |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate… | — | terminated | Sep 26, 2019 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT04441099 | NBE-002 in Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Jun 22, 2020 | NBE-Therapeutics AG | End of Program | Other (stated, no rule matched) |
| NCT04720664 | Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer(OASIS) | Phase 2 | terminated | Jan 22, 2021 | Georgetown University | Lack of efficacy | Efficacy / futility |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 23, 2024source: clinicaltrials